Novalis LifeSciences LLC is a venture capital firm established in 2017 and based in Hampton, New Hampshire. It focuses on investing in small to medium-sized companies within the life sciences sector, specifically targeting biopharma therapeutics, molecular diagnostics, life science tools, genomics, synthetic biology, and agricultural biotechnology. The firm is led by Dr. Marijn E. Dekkers, who has a notable background as the former CEO of Bayer AG and Thermo Fisher Scientific. Novalis collaborates with a diverse group of specialists, each an expert in their respective fields, to identify and support breakthrough technologies that can advance the life sciences industry. As a Registered Investment Adviser, Novalis LifeSciences aims to foster innovation and growth in the life science landscape.
BlueWhale Bio is a spinout from the University of Pennsylvania focused on advancing cell-based therapies through innovative manufacturing techniques. The company develops cell drugs aimed at addressing challenges in gene therapy production, specifically to enhance the effectiveness of cancer treatment. By streamlining the manufacturing process, BlueWhale Bio seeks to facilitate the development of effective cancer treatment plans for patients, ultimately improving outcomes in the field of cell therapy.
Flywheel.io
Series D in 2023
Flywheel is a data management and analysis platform built specifically for scientists and the researcher's workflow. They empower research momentum by focusing on data and medical image capture, content management, scientific computation, and collaboration. With reproducible research in mind, they combine open-source methods from top universities, a modern web user interface, and an extensible compute engine based on containerization technology. The result is a software platform to accelerate discovery and help researchers do science, not IT. Flywheel accelerates new scientific discoveries in life-science, biotech, and academic imaging research through cloud-scale collaboration. As a result, imaging researchers are able to avoid innovation bottlenecks, and accelerate discovery by doing more science, and less IT.
Telesis Bio
Post in 2023
Telesis Bio is a biotech company established in 2013 and headquartered in San Diego, USA. It specializes in synthetic biology, providing researchers with tools to design, code, and create synthetic DNA and mRNA. The company focuses on enabling the rapid, accurate, and reproducible construction of high-quality synthetic genetic material for various applications in synthetic biology. Telesis Bio manufactures and sells laboratory equipment, including synthetic biology instruments, reagents, and related products. Its product offerings include the BioXp system, BioXp kits, benchtop reagents, and BioXp biofoundry services, all aimed at supporting researchers in their scientific endeavors.
Animol Discovery
Series B in 2023
Animol Discovery focuses on developing innovative veterinary medicines through its proprietary drug discovery technology. The company specializes in creating small molecule active pharmaceutical ingredients tailored for the unique needs of veterinary patients. Utilizing a technology platform built on DNA-encoded chemicals, Animol enables accelerated ultra-high throughput screening processes, allowing for the simultaneous evaluation of target and anti-target activities. This approach aims to streamline the discovery of effective treatments for pets, addressing a significant need in the animal health industry. Led by a team of experts with extensive experience in bringing veterinary drugs to market, Animol is committed to advancing the field of veterinary medicine.
Mercy BioAnalytics
Series A in 2023
Mercy BioAnalytics is a biotechnology company based in Natick, Massachusetts, founded in 2018 by Paul Blavin and Joseph Sedlak. The company focuses on improving cancer outcomes through early detection by utilizing a novel liquid biopsy assay platform. This platform analyzes tumor-derived extracellular vesicles (EVs), which are abundant in blood and provide critical information about their parent cells. By leveraging these EVs, Mercy BioAnalytics aims to enable the detection of various types of cancer at its earliest stages, ultimately striving to enhance patient outcomes and save lives.
LevitasBio
Series C in 2022
LevitasBio is focused on advancing cellular analytics through its innovative magnetic levitation technology. This platform, known as LeviCell, allows for the label-free purification of cells and nuclei, enabling researchers to analyze biological signatures without altering or damaging the samples. By overcoming traditional limitations in cellular analysis, LevitasBio's approach facilitates the study of high-value primary samples and sensitive cell types, regardless of their initial conditions. This capability provides significant advantages for scientists in the life sciences and healthcare sectors, allowing for a deeper and more accurate understanding of biological processes.
etherna immunotherapies
Series B in 2022
eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.
Animol Discovery
Series B in 2022
Animol Discovery focuses on developing innovative veterinary medicines through its proprietary drug discovery technology. The company specializes in creating small molecule active pharmaceutical ingredients tailored for the unique needs of veterinary patients. Utilizing a technology platform built on DNA-encoded chemicals, Animol enables accelerated ultra-high throughput screening processes, allowing for the simultaneous evaluation of target and anti-target activities. This approach aims to streamline the discovery of effective treatments for pets, addressing a significant need in the animal health industry. Led by a team of experts with extensive experience in bringing veterinary drugs to market, Animol is committed to advancing the field of veterinary medicine.
Enko Chem
Series C in 2022
Enko Chem, Inc. is a biotechnology company based in Woburn, Massachusetts, that focuses on discovering and developing innovative small-molecule products designed to protect crops from pests and diseases. Founded in 2017, the company utilizes a proprietary technology platform that enables the rapid identification of safe and cost-effective solutions aimed at promoting sustainable food production. Through its efforts, Enko Chem seeks to address the challenges faced by farmers in maintaining crop health while ensuring environmental sustainability.
Vizgen
Series C in 2022
Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.
Sherlock Biosciences
Series B in 2022
Sherlock Biosciences is a biotechnology company based in Cambridge, Massachusetts, focused on developing molecular diagnostic solutions. Incorporated in 2018, the company utilizes cutting-edge engineering biology tools, including CRISPR and synthetic biology, to create innovative diagnostic platforms. Its primary products include SHERLOCK, a CRISPR-based method for detecting and quantifying specific genetic sequences, and INSPECTR, a synthetic biology-based diagnostics platform. These technologies aim to provide rapid, accurate, and affordable results across various applications, including precision oncology, infection identification, food safety, at-home testing, and disease detection. By leveraging these advanced tools, Sherlock Biosciences addresses the need for effective diagnostics in both high and low-resource settings.
Ori Biotech
Series B in 2022
Ori Biotech is a developer of a manufacturing platform designed to enhance access to lifesaving treatments through cell and gene therapies. The company has created a proprietary and flexible manufacturing system that automates and standardizes the production process, facilitating the transition of therapeutics from pre-clinical development to commercial-scale manufacturing. By integrating advanced hardware, software, data, and analytics, Ori Biotech's platform aims to increase throughput, improve quality, and reduce costs for therapeutics developers. This innovative approach is intended to accelerate the commercialization of cell and gene therapies, ultimately providing patients with a new generation of personalized and effective treatments.
SkylineDX
Venture Round in 2021
SkylineDx specializes in developing and commercializing advanced diagnostic tests that leverage gene signature analysis. These tests aid healthcare professionals in making personalized treatment decisions by accurately identifying disease types or status, and predicting patients' responses to specific treatments.
AgBiome
Series D in 2021
AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on developing biological products to address significant challenges in agriculture, particularly soil-borne diseases affecting greenhouse and major row crops. Utilizing advanced genomics and screening technologies, AgBiome identifies plant-associated microbes that can enhance plant health, improve pest resistance, and increase crop yields. The company operates a state-of-the-art laboratory and greenhouse facility and collaborates with prominent agricultural firms to expedite its research and product development. AgBiome's offerings include fungicides that protect crops from various diseases and a platform for capturing and screening diverse microbes for agricultural applications. Established in 2012, AgBiome aims to provide sustainable solutions that support global food production and address critical agricultural issues such as insect and nematode control.
Modality.AI
Seed Round in 2021
Modality.AI, Inc. specializes in AI-driven healthcare screening solutions that focus on monitoring and assessing patients' health through conversational interactions. The company's platform utilizes audio-visual biomarkers and engages patients via dialogue and video to provide continuous health assessments. This technology is particularly beneficial for pharmaceutical companies, as it enhances the efficiency of clinical trials for therapies targeting neurological and mental health conditions. By analyzing multimodal data, Modality.AI delivers objective measures that correlate with clinical outcomes, facilitating self-driven neurological assessments. Founded in 2018 and headquartered in San Francisco, California, Modality.AI aims to improve health evaluations and streamline the clinical trial process.
Allurion
Series D in 2021
Allurion Technologies, Inc. is a medical device company based in Natick, Massachusetts, founded in 2009. It specializes in developing innovative solutions for weight loss, particularly through its flagship product, the Allurion Balloon. This unique intragastric balloon is designed to be swallowed in capsule form, allowing for a non-surgical approach to obesity treatment. Once ingested, the balloon expands in the stomach, promoting a feeling of fullness to aid in weight loss. The company also offers the Allurion Program, which includes AI-powered remote monitoring, a behavior change program, and telehealth services to support patients throughout their weight loss journey. Allurion's approach aims to provide effective weight management without the need for surgery or endoscopy.
Vizgen
Series B in 2021
Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.
Cerevel Therapeutics
Post in 2020
Cerevel Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuroscience diseases. Founded in 2018 and headquartered in Cambridge, Massachusetts, the company is advancing a diverse pipeline that includes five clinical-stage investigational therapies and several preclinical compounds targeting conditions such as schizophrenia, epilepsy, Parkinson's disease, and substance use disorder. Key products under development include CVL-231, a positive allosteric modulator for schizophrenia; CVL-865, which is being tested for drug-resistant focal onset epilepsy and acute anxiety; and Tavapadon, a selective dopamine D1/D5 partial agonist for Parkinson's disease. Cerevel Therapeutics employs a unique approach that leverages expertise in neurocircuitry and receptor selectivity to address unmet medical needs in the field of neuroscience.
Enko Chem
Series B in 2020
Enko Chem, Inc. is a biotechnology company based in Woburn, Massachusetts, that focuses on discovering and developing innovative small-molecule products designed to protect crops from pests and diseases. Founded in 2017, the company utilizes a proprietary technology platform that enables the rapid identification of safe and cost-effective solutions aimed at promoting sustainable food production. Through its efforts, Enko Chem seeks to address the challenges faced by farmers in maintaining crop health while ensuring environmental sustainability.
etherna immunotherapies
Series B in 2020
eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.
Biotalys
Series C in 2020
Biotalys NV is an agricultural technology company based in Ghent, Belgium, that specializes in the research and development of biopesticides aimed at controlling pests and diseases affecting crops and harvested products. The company utilizes its proprietary Agrobody technology platform to create protein-based crop protection solutions that effectively bind to leaves, seeds, and fruits, enabling targeted delivery of active ingredients. This innovative approach combines the performance of traditional chemical pesticides with the safety profile of biological alternatives, making Biotalys' products suitable for both pre- and post-harvest applications. Founded in 2013, Biotalys is committed to providing sustainable and safe food protection solutions, positioning itself as a leader in the evolution of agricultural practices.
Allurion
Venture Round in 2020
Allurion Technologies, Inc. is a medical device company based in Natick, Massachusetts, founded in 2009. It specializes in developing innovative solutions for weight loss, particularly through its flagship product, the Allurion Balloon. This unique intragastric balloon is designed to be swallowed in capsule form, allowing for a non-surgical approach to obesity treatment. Once ingested, the balloon expands in the stomach, promoting a feeling of fullness to aid in weight loss. The company also offers the Allurion Program, which includes AI-powered remote monitoring, a behavior change program, and telehealth services to support patients throughout their weight loss journey. Allurion's approach aims to provide effective weight management without the need for surgery or endoscopy.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.